COVID-19COVIDNCT04416256
COVID-19 Pandemic and Worldwide Organ Procurement
An observational study of COVID-19, run by Paris Translational Research Center for Organ Transplantation at 1 site in France.
Trial summary
End-stage organ failure is estimated to affect more than 4 to 6 million persons worldwide. In 2018, transplant systems across the globe enabled around 150,000 patients to benefit from a kidney, heart, lung, liver, or other solid organ, a number that was far less than the demand. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- COVID-19
- How many people
- 230,000 participants
- Where
- 1 siteFrance
- Study dates
- 1 Feb 2020to Feb 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Solid organ transplants performed during the study period (kidney, lung, heart, liver and combined organs in Europe (France, Spain, Portugal, Germany, Italy, Croatia, Belgium, Netherlands, Austria), North America (US and Canada), Central and South America (Mexico, Brazil, Uruguay, Argentina and Chile) and Oceania (Australia)
Who may be able to join
- All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Paris Transplant Group
Paris, 75015
Alexandre Loupy, +33 1 53 98 80 00, alexandre.loupy@inserm.fr
Alexandre Loupy, MD
About this study
Official title: Consequences of the COVID-19 Pandemic on Worldwide Organ Procurement and Transplantation
End-stage organ failure is estimated to affect more than 4 to 6 million persons worldwide. In 2018, transplant systems across the globe enabled around 150,000 patients to benefit from a kidney, heart, lung, liver, or other solid organ, a number that was far less than the demand. According to data from the World Health Organization, more than 1,500,000 persons live with a transplanted organ worldwide. In the US, approximately 40,000 patients receive an organ transplant every year, but 120,000 still remain waitlisted for transplantation today, with 7,600 dying annually while waiting for an organ transplant. A similar lack of organs and high death rates on the waiting list affect patients in Europe and many other countries.
As nations adjust to new realities driven by the coronavirus (COVID-19) outbreak, many health care providers, institutions and patients are concerned about the potential impact that COVID-19 will have on organ donation and transplantation. One concern is that transplant recipients may have a greater susceptibility to infection and greater viral burden. A second concern is that hospitals will lack the resources in terms of staff and equipment to care for recipients after transplantation, who often require intensive care and multispecialty management.
Because of the overwhelming healthcare system burden, a dramatic negative effect on worldwide organ donation and transplantation is anticipated, but has not been measured. Our objective was to quantify the worldwide impact of COVID-19 pandemic on organ donation and transplantation and consequences for waitlisted patients.
- Conditions
- COVID-19
- Keywords
- organ, procurement, transplantation, pandemic
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| France | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Spain | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Portugal | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Croatia | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Germany | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Italy | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Netherlands | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Austria | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| US | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Canada | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Mexico | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Brazil | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Uruguay | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Argentina | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Chile | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Australia | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Belgium | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. | |
| Finland | All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Organ transplantation activity during COVID-19 pandemic
Overall deceased donor transplantation performed during the COVID-19 pandemic. Stratified analysis by deceased donor type (Kidney, lung, Liver, heart), and combined transplantations during the COVID-19 pandemic.
Measured: Two years since COVID-19 outbreak.
Secondary outcomes (1)
Further analysis on organ transplantation with stratification
Geographic disparities related to organ transplantation rates and association with COVID-19 clusters Living donor transplantation performed during the COVID-19 pandemic. Quality of transplanted organs (kidney) before and after the COVID-19 pandemic. Change in relationship between living donors and their recipients before and after the COVID-19 pandemic.
Measured: Two years since COVID-19 outbreak.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2020
- Study start1 Feb 2020
- Primary completionFeb 2022 (estimated)
- Study completionFeb 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 230,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Paris Translational Research Center for Organ Transplantation
- Sponsor type
- University, hospital or other
- Collaborators
- Agence de La Biomédecine, Eurotransplant, United Network for Organ Sharing, Deutsche Stiftung Organtransplantation, Centro Nazionale Trapianti, Brazilian Organ Transplant Association, The Canadian Association of Transplantation, Scandiatransplant, Nederlandse Transplantatie Vereniging, Austrotransplant, Centro Nacional de Trasplantes, Instituto Nacional de Donación y Trasplante de Células, Tejidos y Órganos, Donor Network of Croatia, Instituto Nacional Central Único Coordinador de Ablación e Implante, Corporación Nacional de Trasplantes de Chile, Australian Organ and Tissue Donation and Transplantation Authority, Organización Nacional de Trasplantes, Autoridade Para Services de Sangue e Transplantacáo
- Responsible party
- Sponsor
- Investigators
- Alexandre Loupy, Principal investigator, Paris Translational Research Center for Organ Transplantation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04416256
- Sponsor's protocol ID
- COVID/W.W.
- Acronym
- COVID
- Status last verified
- Jun 2020
- First submitted
- 29 May 2020
- Last updated
- 4 Jun 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Xu B, Kraemer MUG; Open COVID-19 Data Curation Group. Open access epidemiological data from the COVID-19 outbreak. Lancet Infect Dis. 2020 May;20(5):534. doi: 10.1016/S1473-3099(20)30119-5. Epub 2020 Feb 19. No abstract available.
PubMed 32087115Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020 Mar 21;395(10228):931-934. doi: 10.1016/S0140-6736(20)30567-5. Epub 2020 Mar 9. No abstract available.
PubMed 32164834Ahn C, Amer H, Anglicheau D, Ascher NL, Baan CC, Battsetset G, Bat-Ireedui B, Berney T, Betjes MGH, Bichu S, Birn H, Brennan D, Bromberg J, Caillard S, Cannon RM, Cantarovich M, Chan A, Chen ZS, Chapman JR, Cole EH, Cross N, Durand F, Egawa H, Emond JC, Farrero M, Friend PJ, Geissler EK, Ha J, Haberal MA, Henderson ML, Hesselink DA, Humar A, Jassem W, Jeong JC, Kaplan B, Kee T, Kim SJ, Kumar D, Legendre CM, Man K, Moulin B, Muller E, Munkhbat R, Od-Erdene L, Perrin P, Rela M, Tanabe K, Tedesco Silva H, Tinckam KT, Tullius SG, Wong G. Global Transplantation COVID Report March 2020. Transplantation. 2020 Oct;104(10):1974-1983. doi: 10.1097/TP.0000000000003258. No abstract available.
PubMed 32243281Zhang X. Epidemiology of Covid-19. N Engl J Med. 2020 May 7;382(19):1869. doi: 10.1056/NEJMc2005157. Epub 2020 Mar 27. No abstract available.
PubMed 32220200Martino F, Plebani M, Ronco C. Kidney transplant programmes during the COVID-19 pandemic. Lancet Respir Med. 2020 May;8(5):e39. doi: 10.1016/S2213-2600(20)30182-X. Epub 2020 Apr 16. No abstract available.
PubMed 32305079Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, Ross M, Forest S, Goldstein YD, Ajaimy M, Liriano-Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Rocca J, Kinkhabwala M. Covid-19 and Kidney Transplantation. N Engl J Med. 2020 Jun 18;382(25):2475-2477. doi: 10.1056/NEJMc2011117. Epub 2020 Apr 24. No abstract available.
PubMed 32329975Coates PT, Wong G, Drueke T, Rovin B, Ronco P; Associate Editors, for the Entire Editorial Team. Early experience with COVID-19 in kidney transplantation. Kidney Int. 2020 Jun;97(6):1074-1075. doi: 10.1016/j.kint.2020.04.001. Epub 2020 Apr 9. No abstract available.
PubMed 32354635Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020 Apr 14;323(14):1335. doi: 10.1001/jama.2020.4344. No abstract available.
PubMed 32181795Omer SB, Malani P, Del Rio C. The COVID-19 Pandemic in the US: A Clinical Update. JAMA. 2020 May 12;323(18):1767-1768. doi: 10.1001/jama.2020.5788. No abstract available.
PubMed 32250388Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 May;20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1. Epub 2020 Feb 19. No abstract available.
PubMed 32087114Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJL, Jardine M, Kasiske B, Kottgen A, Kretzler M, Levey AS, Luyckx VA, Mehta R, Moe O, Obrador G, Pannu N, Parikh CR, Perkovic V, Pollock C, Stenvinkel P, Tuttle KR, Wheeler DC, Eckardt KU; ISN Global Kidney Health Summit participants. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017 Oct 21;390(10105):1888-1917. doi: 10.1016/S0140-6736(17)30788-2. Epub 2017 Apr 20.
PubMed 28434650Aubert O, Yoo D, Zielinski D, Cozzi E, Cardillo M, Durr M, Dominguez-Gil B, Coll E, Da Silva MI, Sallinen V, Lemstrom K, Midtvedt K, Ulloa C, Immer F, Weissenbacher A, Vallant N, Basic-Jukic N, Tanabe K, Papatheodoridis G, Menoudakou G, Torres M, Soratti C, Hansen Krogh D, Lefaucheur C, Ferreira G, Silva HT Jr, Hartell D, Forsythe J, Mumford L, Reese PP, Kerbaul F, Jacquelinet C, Vogelaar S, Papalois V, Loupy A. COVID-19 pandemic and worldwide organ transplantation: a population-based study. Lancet Public Health. 2021 Oct;6(10):e709-e719. doi: 10.1016/S2468-2667(21)00200-0. Epub 2021 Aug 30.
PubMed 34474014
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Consequences of the COVID-19 Pandemic on Worldwide Organ Procurement and Transplantation
- ClinicalTrials.gov ID
- NCT04416256
- Acronym / sponsor ID
- COVID / COVID/W.W.
- Conditions
- COVID-19
- Keywords
- organ, procurement, transplantation, pandemic
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 230,000 participants (estimated)
- Lead sponsor
- Paris Translational Research Center for Organ TransplantationUniversity, hospital or other
- Collaborators
- Agence de La Biomédecine, Eurotransplant, United Network for Organ Sharing, Deutsche Stiftung Organtransplantation, Centro Nazionale Trapianti, Brazilian Organ Transplant Association, The Canadian Association of Transplantation, Scandiatransplant, Nederlandse Transplantatie Vereniging, Austrotransplant, Centro Nacional de Trasplantes, Instituto Nacional de Donación y Trasplante de Células, Tejidos y Órganos, Donor Network of Croatia, Instituto Nacional Central Único Coordinador de Ablación e Implante, Corporación Nacional de Trasplantes de Chile, Australian Organ and Tissue Donation and Transplantation Authority, Organización Nacional de Trasplantes, Autoridade Para Services de Sangue e Transplantacáo
- Study start
- 1 Feb 2020 (actual)
- Primary completion
- Feb 2022 (estimated)
- Study completion
- Feb 2022 (estimated)
- First posted
- 4 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
End-stage organ failure is estimated to affect more than 4 to 6 million persons worldwide. In 2018, transplant systems across the globe enabled around 150,000 patients to benefit from a kidney, heart, lung, liver, or other solid organ, a number that was far less than the demand. According to data from the World Health Organization, more than 1,500,000 persons live with a transplanted organ worldwide. In the US, approximately 40,000 patients receive an organ transplant every year, but 120,000 still remain waitlisted for transplantation today, with 7,600 dying annually while waiting for an organ transplant. A similar lack of organs and high death rates on the waiting list affect patients in Europe and many other countries.
As nations adjust to new realities driven by the coronavirus (COVID-19) outbreak, many health care providers, institutions and patients are concerned about the potential impact that COVID-19 will have on organ donation and transplantation. One concern is that transplant recipients may have a greater susceptibility to infection and greater viral burden. A second concern is that hospitals will lack the resources in terms of staff and equipment to care for recipients after transplantation, who often require intensive care and multispecialty management.
Because of the overwhelming healthcare system burden, a dramatic negative effect on worldwide organ donation and transplantation is anticipated, but has not been measured. Our objective was to quantify the worldwide impact of COVID-19 pandemic on organ donation and transplantation and consequences for waitlisted patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 18
| Arm | Type | Receives |
|---|---|---|
| France | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Spain | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Portugal | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Croatia | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Germany | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Italy | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Netherlands | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Austria | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| US | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Canada | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Mexico | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Brazil | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Uruguay | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Argentina | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Chile | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Australia | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Belgium | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
| Finland | – | –All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Solid organ transplants performed during the study period (kidney, lung, heart, liver and combined organs in Europe (France, Spain, Portugal, Germany, Italy, Croatia, Belgium, Netherlands, Austria), North America (US and Canada), Central and South America (Mexico, Brazil, Uruguay, Argentina and Chile) and Oceania (Australia)
Key inclusion criteria (1 listed)
- All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Organ transplantation activity during COVID-19 pandemic
Time frame: Two years since COVID-19 outbreak.
Overall deceased donor transplantation performed during the COVID-19 pandemic. Stratified analysis by deceased donor type (Kidney, lung, Liver, heart), and combined transplantations during the COVID-19 pandemic.
1 secondary outcome
Further analysis on organ transplantation with stratification
Time frame: Two years since COVID-19 outbreak.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2020.
- Background: PubMed 32087115Xu B, Kraemer MUG; Open COVID-19 Data Curation Group. Open access epidemiological data from the COVID-19 outbreak. Lancet Infect Dis. 2020 May;20(5):534. doi: 10.1016/S1473-3099(20)30119-5. Epub 2020 Feb 19. No abstract available.
- Background: PubMed 32164834Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020 Mar 21;395(10228):931-934. doi: 10.1016/S0140-6736(20)30567-5. Epub 2020 Mar 9. No abstract available.
- Background: PubMed 32243281Ahn C, Amer H, Anglicheau D, Ascher NL, Baan CC, Battsetset G, Bat-Ireedui B, Berney T, Betjes MGH, Bichu S, Birn H, Brennan D, Bromberg J, Caillard S, Cannon RM, Cantarovich M, Chan A, Chen ZS, Chapman JR, Cole EH, Cross N, Durand F, Egawa H, Emond JC, Farrero M, Friend PJ, Geissler EK, Ha J, Haberal MA, Henderson ML, Hesselink DA, Humar A, Jassem W, Jeong JC, Kaplan B, Kee T, Kim SJ, Kumar D, Legendre CM, Man K, Moulin B, Muller E, Munkhbat R, Od-Erdene L, Perrin P, Rela M, Tanabe K, Tedesco Silva H, Tinckam KT, Tullius SG, Wong G. Global Transplantation COVID Report March 2020. Transplantation. 2020 Oct;104(10):1974-1983. doi: 10.1097/TP.0000000000003258. No abstract available.
- Background: PubMed 32220200Zhang X. Epidemiology of Covid-19. N Engl J Med. 2020 May 7;382(19):1869. doi: 10.1056/NEJMc2005157. Epub 2020 Mar 27. No abstract available.
- Background: PubMed 32305079Martino F, Plebani M, Ronco C. Kidney transplant programmes during the COVID-19 pandemic. Lancet Respir Med. 2020 May;8(5):e39. doi: 10.1016/S2213-2600(20)30182-X. Epub 2020 Apr 16. No abstract available.
- Background: PubMed 32329975Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, Ross M, Forest S, Goldstein YD, Ajaimy M, Liriano-Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Rocca J, Kinkhabwala M. Covid-19 and Kidney Transplantation. N Engl J Med. 2020 Jun 18;382(25):2475-2477. doi: 10.1056/NEJMc2011117. Epub 2020 Apr 24. No abstract available.
- Background: PubMed 32354635Coates PT, Wong G, Drueke T, Rovin B, Ronco P; Associate Editors, for the Entire Editorial Team. Early experience with COVID-19 in kidney transplantation. Kidney Int. 2020 Jun;97(6):1074-1075. doi: 10.1016/j.kint.2020.04.001. Epub 2020 Apr 9. No abstract available.
- Background: PubMed 32181795Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020 Apr 14;323(14):1335. doi: 10.1001/jama.2020.4344. No abstract available.
- Background: PubMed 32250388Omer SB, Malani P, Del Rio C. The COVID-19 Pandemic in the US: A Clinical Update. JAMA. 2020 May 12;323(18):1767-1768. doi: 10.1001/jama.2020.5788. No abstract available.
- Background: PubMed 32087114Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 May;20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1. Epub 2020 Feb 19. No abstract available.
- Results publication: PubMed 28434650Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJL, Jardine M, Kasiske B, Kottgen A, Kretzler M, Levey AS, Luyckx VA, Mehta R, Moe O, Obrador G, Pannu N, Parikh CR, Perkovic V, Pollock C, Stenvinkel P, Tuttle KR, Wheeler DC, Eckardt KU; ISN Global Kidney Health Summit participants. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017 Oct 21;390(10105):1888-1917. doi: 10.1016/S0140-6736(17)30788-2. Epub 2017 Apr 20.
- Derived from this study: PubMed 34474014Aubert O, Yoo D, Zielinski D, Cozzi E, Cardillo M, Durr M, Dominguez-Gil B, Coll E, Da Silva MI, Sallinen V, Lemstrom K, Midtvedt K, Ulloa C, Immer F, Weissenbacher A, Vallant N, Basic-Jukic N, Tanabe K, Papatheodoridis G, Menoudakou G, Torres M, Soratti C, Hansen Krogh D, Lefaucheur C, Ferreira G, Silva HT Jr, Hartell D, Forsythe J, Mumford L, Reese PP, Kerbaul F, Jacquelinet C, Vogelaar S, Papalois V, Loupy A. COVID-19 pandemic and worldwide organ transplantation: a population-based study. Lancet Public Health. 2021 Oct;6(10):e709-e719. doi: 10.1016/S2468-2667(21)00200-0. Epub 2021 Aug 30.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexandre Loupy principal investigator
Paris Translational Research Center for Organ Transplantation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Paris Translational Research Center for Organ Transplantation at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Alexandre Loupy (+33 1 53 98 80 00, alexandre.loupy@inserm.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Organ transplantation activity during COVID-19 pandemic (time frame: Two years since COVID-19 outbreak.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04416256, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2020; AzTrials last refreshed its copy on 6 Nov 2026.